What happens when habit stops driving demand?
Hi there and happy Wednesday,
Imagine waking up one day and simply not wanting your morning coffee. No willpower involved. No health kick. You just... stopped wanting it. Now scale that to 1 in 8 North American adults, and replace coffee with snacks, beer, cigarettes, and fast food.
Call it a neurological event, because that's what it is. The effects are already showing up across consumer markets.
GLP-1 drugs, Ozempic, Wegovy, Mounjaro, are the fastest-adopted class of medication in modern history. The non-diabetic user base grew 700% between 2019 and 2023. They're not just shrinking waistlines. They're rewiring the brain's reward system, the same circuitry that makes habits sticky, purchases repeat, and cravings feel irresistible.
For companies that rely on repeat consumption, the real story isn't weight loss. It's the shift in the underlying behaviors that create demand.
So here's the real question:
Is your strategy built for the consumer's appetite, or for their neurology? Because one of those just changed.

The industry response got the problem wrong
The food world moved fast. Nestlé launched a high-protein GLP-1 meal line. Herbalife rolled out a nutrition companion. The entire category organized around one assumption: these users need help eating less.
They don't. Appetite suppression is the one thing the drug already handles. Grocery spend dropped 5.5% within six months of starting therapy. Fast food fell over 8%. Calorie-dense snack purchases dropped 11%.

The real gap is micronutrients: Calcium, vitamin D, magnesium, collagen, zinc.
When caloric intake drops and stays low, access to these nutrients collapses with it. No protein shake on the market addresses that with the specificity this population actually needs.
The risk accumulating in silence
The industry spotted muscle loss and responded. Fitness brands built GLP-1 protocols. Protein got repositioned.
Bone density loss is getting none of that attention.
A 2024 randomized study found users on liraglutide without an exercise protocol showed significant bone mineral density reductions at the hip and lumbar spine over 52 weeks. The clinical signal is documented. The product response doesn't exist yet.
Bone loss produces no fatigue, no visible weakness, no consumer complaint. It shows up years later as a fracture or a diagnosis. The brands that name this category first will hold a window that won't stay open long.

The sector you're in doesn't matter as much as you think
The alcohol numbers are where this gets genuinely strange. In controlled trials, semaglutide drove a 41% reduction in consumption and 64% of participants reached zero heavy drinking days within eight weeks.
That has nothing to do with diet. GLP-1 receptors sit inside the brain's reward circuitry. When activated, the dopamine response to all reward stimuli gets dampened. Food, alcohol, nicotine, the mechanism doesn't distinguish. A 2025 trial found exenatide nearly doubled smoking abstinence rates, regardless of BMI.
Loyalty programs, subscription models, impulse purchasing, engagement-driven platforms. The neurological mechanism the drug targets doesn't care which industry you're in.

The biggest opportunity has no owner yet
75% of GLP-1 users want behavioral support during treatment. 17% are receiving it.
That 58-point gap is a market waiting to be built. Telehealth, nutrition counseling, fitness programming, behavioral health, wrapped into a single compounding relationship with the user. The Wisp-Nourish partnership gestures in the right direction, but nothing comprehensive exists at scale.
A supplement SKU competes on shelf. A platform compounds over time. That position doesn't yet exist, and nobody is racing toward it.
Three things worth doing this week
- Audit which revenue lines depend on habitual repurchase and stress-test them against a consumer whose craving no longer fires.
- Get your team reading the bone density data, not just the muscle loss headlines. The invisible risk is where the first-mover window is widest.
- Decide whether your GLP-1 response is a product or a relationship. The answer determines your ceiling.



